

Managed Growth Fund

Fund Focus - January 2022



Investment Strategy

The Fund invests in a mix of Australian and international shares, fixed interest securities, listed property securities and cash. The Fund is designed to reduce investment risk by diversifying across asset classes.

Portfolio Characteristics

Funds Under Management	\$71.25m
Latest Distribution Date	31 December 2021
Latest Distribution Amount	0.5503
Benchmark	CPI+2.5% pa over rolling five year periods before fees and taxes.

Fund Facts

APIR Code	ZUR0059AU
Inception Date	2 April 1997
Total Est. Management Cost %	0.96
Est. Transactional Op. Cost %	0
Buy/Sell Spread %	0.12
Distribution Frequency	Quarterly
Underlying Fund Manager	Australian Shares Antares Capital Partners..

Fund Performance After Fees

	1 Month	3 Months	1 Year	3 Years	5 Years	Since Inception
Distribution	0.00	0.41	7.75	9.33	11.25	6.48
Growth	-2.66	-1.27	1.87	-0.79	-3.65	1.01
Total	-2.66	-0.85	9.62	8.54	7.60	7.49
Benchmark	-2.77	-0.42	10.10	9.66	8.38	7.57

Strategic Investment Partners

Australian Shares

Antares Capital Partners
Celeste Funds Management Pty Limited
DWS International
Schroder Investment Management Australia
Tyndall Asset Management

International Shares

American Century Investment Management, Inc
Epoch Investment Partners, Inc
Lazard Asset Management Pacific Co
Realindex Investments Pty Limited
Allspring Global Investments

Australian Property Securities

Renaissance Property Securities Pty Ltd

Global Property Securities

Presima Inc

Fixed Interest and Cash

Schroder Investment Management Australia

Infrastructure

Lazard Asset Management Pacific Co

Alternative Investments

Insight Investment Management (Global)
Robeco Hong Kong Ltd

Absolute Return Bond

AllianceBernstein Investment Management


Risk Statistics

1 Feb 2017 to 31 Jan 2022


Std Dev	8.65
Sharpe Ratio (arith)	0.88

Investment Growth (\$10,000)

1 Feb 2017 to 31 Jan 2022



Portfolio Equity Sectors (%)



● Absolute Return Bonds	8.29
● Alternatives	9.20
● Australian Property	1.86
● Australian Shares	28.92
● Diversified Fixed Interest	11.85
● Global Property	1.78
● Infrastructure	2.06
● International Shares	28.90
● Liquidity	7.14

Actual Asset Allocation

	Actual Asset Allocation %	Benchmark Weight %	Active Position %
Absolute Return Bonds	8.3	8.0	0.3
Alternatives	9.2	9.0	0.2
Australian Property	1.9	2.0	-0.1
Australian Shares	28.9	29.0	-0.1
Diversified Fixed Interest	11.8	16.0	-4.2
Global Property	1.8	2.0	-0.2
Infrastructure	2.1	2.0	0.1
International Shares	28.9	28.0	0.9
Liquidity	7.1	4.0	3.1

Market Commentary

The Zurich Investments Managed Growth Fund fell by 2.66% in January.

Amid heightened volatility, world stocks prices slid in January as markets reset in nervous anticipation of changes in the global monetary landscape.

In the wake of the US Federal Reserve's (Fed) announcement last month that it would pull back on its extraordinary monetary support, all eyes were on the US central bank and its next move. With US inflation near a 40-year high, and amid indications that the Omicron coronavirus variant is considerably milder than earlier strains, investors worried that the Fed would have significant room to aggressively tackle surging prices. The Fed's announcement in late January that it was on track to raise interest rates in mid-March was expected; however, its unwillingness to commit to a pre-set course, thus opened the door to more frequent and potentially larger hikes than anticipated. This unnerved investors, who were fearful that raising interest rates too quickly or too much could have an adverse impact on corporate profits, consumer demand, and the fragile global economic recovery. Higher interest rates would also increase selling pressure on US government bonds, thereby driving yields upward and undercutting the appeal of stocks.

US Health care stocks lagged in January as the sector's performance was hurt by the ongoing pandemic, which is overwhelming health care providers and disrupting traditional care services and procedures. In addition, the more growth-oriented health care industries were caught up in the broader sell-off, which especially weighed on high-growth equities. Value outperformed growth as larger, more value-oriented pharmaceuticals shares held up best, buoyed by vaccine providers. Despite their disappointing recent stock performance, health care stocks have consistently produced strong earnings growth. In addition, four novel treatments won approval from the Food and Drug Agency in January following a very strong 2021 for drug discovery and approval.

After rising through 2021, the S&P/ASX Small Ordinaries Index plunged in January as markets braced themselves for faster than expected tightening of monetary policy from the Reserve Bank of Australia (RBA) and other major central banks around the world.

The AREIT market tumbled by 9.45% in January as increasing concern over global inflationary pressures saw Central Banks, and particularly the US Federal Reserve, signal intentions to start withdrawing monetary policy support in coming months. Consequently, global bond yields surged and equity markets sold off.

* Performance returns quoted are compound rates of return calculated on exit prices and assume reinvestment of distributions. Returns are calculated net of all ongoing fees and any taxes payable by the fund. Total return includes both growth and distribution returns. Growth return is the change in exit price over the relevant period. The benchmark return shown is a gross return. Please note that figures shown are rounded to one decimal place, therefore some rounding errors may occur.

^ The Estimated Total Management Cost of 0.96% includes an Estimated Performance Fee of 0% and Estimated Indirect Costs of 0.09%.

Past performance is not a reliable indicator of future performance.

This report is issued by Zurich Investment Management Limited ABN: 56 063 278 400, AFSL: 232511, GIIN: FVHHKJ.00012.ME.036 : . The information in the report has been derived from sources reasonably believed to be reliable and accurate and is to be used for research purposes only. Subject to law, none of the companies of the Zurich Financial Services Australia Limited Group, nor their directors or employees, gives any representation or warranty as to the reliability, accuracy or completeness of the information, nor accepts any responsibility arising in any way (including by reason of negligence) from errors in or omissions from, the information provided. A Product Disclosure Statement (PDS) for the Fund is available and can be obtained by calling Zurich Investments on 131 551. The PDS should be considered in deciding whether to acquire, or to continue to hold, an investment in the fund. This information is of a general nature only and does not take into account the investment objectives, financial situation or particular needs of any investor and should not be taken as a securities or stock recommendation. These factors should be considered before any investment decision is made in relation to the fund. Furthermore, this product has been designed to meet certain objectives, financial situations and needs, which are described in our Target Market Determination available at zurich.com.au/tmd

PIRD-018221-2022